Trevena, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
  • Pipeline
    • Overview
    • TRV045
    • TRV250
    • TRV734
  • Products
    • OLINVYKâ„¢ (oliceridine) injection
  • Medical Affairs
    • Investigator-Initiated Trials
    • Contact Medical Information
  • Publications
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financial Info
    • Stock Info
    • Resources
    • Governance
  • Careers
  • Contact
    • Contact Medical Information
    • Whistleblower Hotline

Press Releases

Investors

Investors

  • Overview
  • Press Releases
  • Events & Presentations
    • Presentations
    • IR Calendar
  • Financial Info
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Stock Info
    • Quote
    • Analyst Coverage
    • IRS Form 8937
  • Resources
    • Email Alerts
    • Contacts
    • FAQ
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Governance Documents

Trevena Appoints Francois Nader, MD, to its Board of Directors

Jan 08, 2014 7:00am EST

First Clinical Experience of Trevena's lead CNS Biased Ligand, TRV130, Published in Journal of Clinical Pharmacology

Oct 15, 2013 8:00am EDT

Trevena Files Registration Statement for Proposed Initial Public Offering

Oct 10, 2013 7:00am EDT

Trevena Appoints Roberto Cuca as Senior Vice President & Chief Financial Officer

Sep 17, 2013 1:18pm EDT

Mechanism for Cardiac Effects of Trevena Angiotensin Receptor Biased Ligands Examined in Published Study

Jul 30, 2013 7:00am EDT

Trevena Granted Key Composition of Matter Patent for TRV027 in U.S.

Jul 17, 2013 7:00am EDT

Journal of Clinical Pharmacology Publishes First Clinical Experience with Trevena's Heart Failure Biased Ligand TRV027

Jul 08, 2013 7:00am EDT

Trevena, Inc. and Forest Laboratories Announce a Collaborative Agreement For Development of TRV027 for the Treatment of Acute Heart Failure

May 09, 2013 6:00am EDT

Trevena, Inc. to Present at the 12th Annual Needham Healthcare Conference

Apr 22, 2013 9:00am EDT

Trevena to Present First-in-Man Study Results for Mu-Opioid Biased Ligand TRV130

Mar 18, 2013 9:00am EDT
RSS
  • Prev
    • 1...
    • 22
    • 23
    • 24
    • 25
    • 26
    • 27
    • 28
    • 29
    • 30
    • 31
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
    © 2023 Trevena, Inc. All Rights Reserved.
    Privacy Policy Terms of Use Disclaimer Sitemap